12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AMT-021: Phase I started

uniQure began an open-label Spanish Phase I trial to evaluate a single IV injection of AMT-021 in 8 patients with severe acute intermittent porphyria. The trial is being conducted under the AIPGENE...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >